title: Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
abstract: This study is the first to evaluate biological response to first injections of interferon-beta (IFNbeta) in patients with multiple sclerosis. MxA mRNA was measured in 96 patients receiving IFNbeta-1a (Avonex, n=32), IFNbeta-1b (Betaferon, n=19), IFNbeta-1a (Rebif) 22 microg (n=30), or IFNbeta-1a 44 microg (n=15). Patients were analysed before, 3 and 24 h after the first injection, and 12 h after the second administration. Results showed that up-regulation was evident within 3 h of IFNbeta injection, peaked 12 h after injection, and progressively declined 24 h after administration. The cumulative responses were similar after a single administration, regardless of product/dose. Moreover, data indicate that the abolition of the biological activity detected during IFNbeta therapy is due to underlying phenomena (e.g., neutralizing antibodies), because all patients were constitutively responders to IFNbeta at treatment initiation.
authors.affiliation: Centro di Riferimento Regionale Sclerosi Multipla (CReSM) and Neurobiologia Clinica, Ospedale S. Luigi Gonzaga, Regione Gonzole 10, I-10043, Orbassano, Turino, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Gilli
authors.forename: F
authors.initials: F
authors.lastname: Marnetto
authors.forename: M
authors.initials: M
authors.lastname: Caldano
authors.forename: A
authors.initials: A
authors.lastname: Sala
authors.forename: S
authors.initials: S
authors.lastname: Malucchi
authors.forename: A
authors.initials: A
authors.lastname: Di Sapio
authors.forename: M
authors.initials: M
authors.lastname: Capobianco
authors.forename: A
authors.initials: A
authors.lastname: Bertolotto
mesh_terms: D000328:Adult; D019540:Area Under Curve; D003710:Demography; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005260:Female; D019204:GTP-Binding Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000378:metabolism*; D064547:Myxovirus Resistance Proteins; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013997:Time Factors
chemical_list: D007155:Immunologic Factors; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D012333:RNA, Messenger; D000068576:Interferon beta-1b; D016899:Interferon-beta; D019204:GTP-Binding Proteins; D000068556:Interferon beta-1a